AOL Money & Finance

Bristol-Myers Squibb (BMY) rides Plavix sales to higher earnings

Posted Oct 25th 2007 12:44PM by Beth Gaston MoonBeth Gaston Moon RSS Feed
Filed under: Earnings reports, Products and services, Bristol-Myers Squibb (BMY)

More

Bristol-Myers Squibb (NYSE: BMY) announced today that third-quarter earnings were solidly higher, resulting in an increased target for overall 2007 earnings. In the latest reporting period, the drug manufacturer posted net income of $858 million, or 43 cents per share, up from a year-ago profit of $338 million (17 cents per share). Excluding items, the company banked 38 cents per share, or a penny better than Wall Street's expectations.

Revenue was higher during the period as well, up 22% to $5.05 billion, edging out analysts' consensus view of $5.02 billion.

Helping the company achieve these robust profits was BMY's blood-thinning medication Plavix, which saw sales double to $1.25 billion. The company is continuing a legal battle with Apotex over a generic version of Plavix, which hit shelves last August but has been pulled amid a patent dispute. The Plavix patent is scheduled to expire in 2011. Generic competition had negative repercussions for cholesterol drug Pravachol, which saw sales drop 55% in the third quarter as a result.
But for now, BMY looks forward to a positive fourth quarter. Excluding items, BMY now expects to earn $1.42 to $1.47 per share in the current reporting period, up from prior targets of $1.35 to $1.45 per share and surrounding analysts' per-share estimates of $1.44. For 2008, BMY officials expect to bank between $1.60 and $1.70 per share, excluding restructuring charges and other items. Wall Street is counting on the top end of this range, looking for $1.70 per share in the next fiscal year.

In late-morning trading, BMY shares have jumped 2.4% higher, but so far have been unable to hurdle their 10-day moving average, hovering menacingly overhead. Earlier this week, the trendline crossed below the stock's 20-day moving average, which can be a bearish technical sign.

Beth Gaston Moon is an analyst at Schaeffer's Investment Research.

Visit AOL Money & Finance for more earnings coverage

Tags: Apotex, BMY, earnings, inthenews, Plavix, Pravachol, revenue

Symbol Lookup
IndexesChangePrice
DJIA+203.5210,226.94
NASDAQ+41.622,154.06
S&P 500+23.781,093.08

Last updated: November 10, 2009: 02:29 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

    BioHealth Investor Headlines

    WalletPop Headlines

    My Portfolios

    Track your stocks here!

    Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

    • My Portfolio
    • Create a New Portfolio

    BloggingStocks Partners

    More from AOL Money & Finance

    WalletPop Headlines